Drug profile · INN
sitagliptin + metformin
JANUMET XR
sitagliptin + metformin (JANUMET XR) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sitagliptin + metformin
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
sitagliptin + metformin (JANUMET XR) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd.
Key facts
INN sitagliptin + metformin
Brand JANUMET XR
Mechanism Dipeptidyl peptidase IV inhibitor
Target Dipeptidyl peptidase 4
Originator Alphapharm Pty Ltd
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sitagliptin + metformin?
sitagliptin + metformin (JANUMET XR) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd.
What is the brand name for sitagliptin + metformin?
JANUMET XR is a marketed brand name for sitagliptin + metformin. Check FDA Drugs@FDA for the current US label holder and prescribing information.